AbbVie Touts Additional Rinvoq Data In Inflammatory Spinal Arthritis

AbbVie Inc ABBV has churned out new data for Rinvoq in the hope that adding more evidence will back the JAK inhibitor's megablockbuster potential.
Related: AbbVie Submits Upadacitinib Applications In US, Europe For Ulcerative Colitis.
The first study, part of the Phase 3 SELECT-AXIS 2 trial, looked at ankylosing spondylitis, characterized by structural damage of their sacroiliac joints visible on x-rays in 420 patients.
At week 14, 45% of patients on Rinvoq achieved an Assessment in Spondyloarthritis International Society 40 response, compared to just 18% of those who took a placebo.
Patients treated with the drug saw statistically significant reductions in signs and symptoms, including back pain and inflammation and improvements in physical function and disease activity.
In the second study, 45% of patients with non-radiographic axial spondyloarthritis achieved ASAS 40, compared to just 23% of patients on placebo.
AbbVie already has an application under review with the FDA and approved in Europe for ankylosing spondylitis.
The trial also met several secondary endpoints. Significantly more Rinvoq patients achieved low disease activity and achieved better improvements on MRI scans than placebo.
Related: FDA Hits JAK inhibitors With Heart Safety, Cancer Warnings: All You Need To Know.
Price Action: ABBV stock is up 2.00% at $111.51 during the market session on the last check Thursday.